Live Breaking News & Updates on Clinical Research Team For Leukemias

Stay updated with breaking news from Clinical research team for leukemias. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs. ....

United States , New Haven , Samer Zeidan , Daiichi Sankyo , States Cerner Enviza , Boehringer Ingelheim Incyte , Myeloid Malignancies At Yale Cancer Center , Early Therapeutics Research , Clinical Research Team For Leukemias , American Society Of Hematology , Annual Meeting , Clinical Research Team , Myeloid Malignancies , Yale Cancer Center , End Results , United States Cerner Enviza , Charlson Comorbidity Index , Medicare Advantage , Seattle Genetics , Lox Oncology , Shattuck Labs , Lymphoma Myeloma ,

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome. ....

United States , New Haven , Samer Zeidan , Daiichi Sankyo , States Cerner Enviza , Boehringer Ingelheim Incyte , Myeloid Malignancies At Yale Cancer Center , Early Therapeutics Research , Clinical Research Team For Leukemias , Clinical Research Team , Myeloid Malignancies , Yale Cancer Center , End Results , United States Cerner Enviza , Charlson Comorbidity Index , Medicare Advantage , Seattle Genetics , Lox Oncology , Shattuck Labs , Lymphoma Myeloma , Oral Decitabine Cedazuridine , Parenteral Hypomethylating Agents , Intravenous Subcutaneous Hypomethylating Agents , Patients With Myelodysplastic Syndrome ,

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population. ....

United States , New Haven , Guillermo Garcia Manero , Samer Zeidan , Ashling Wahner , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Yale School Of Medicine , Bristol Myers Squibb , Department Of Leukemia , Hematologic Malignancies At Yale Cancer Center , Translational Research , Early Therapeutics Research In Hematology , Clinical Research Team For Leukemias , Myelodysplastic Syndromes , Cancer Medicine , Cancer Center , Yale School , Early Therapeutics Research , Clinical Research Team , Myeloid Malignancies , Hematologic Malignancies , Yale Cancer Center , Drs Garcia Manero , Bristol Myers , Apple Podcasts ,